What is the safety and efficacy of combining vortioxetine (Trintellix) with mirtazapine to treat insomnia?

Combining Trintellix (Vortioxetine) and Mirtazapine for Sleep

I do not recommend combining vortioxetine (Trintellix) with mirtazapine specifically for insomnia treatment, as this combination lacks evidence for efficacy or safety and carries significant risk of serotonin syndrome.

Why This Combination Is Problematic

Serotonin Syndrome Risk

Both vortioxetine and mirtazapine are serotonergic agents. The FDA label for Trintellix explicitly warns about combining it with other serotonergic drugs, stating that concurrent use "may result in serotonin syndrome" 1. While mirtazapine is not listed as a contraindication like MAOIs, the combination increases serotonergic activity beyond what either agent does alone, creating unnecessary risk without proven benefit.

Lack of Evidence for the Combination

There are no studies evaluating the safety or efficacy of combining vortioxetine with mirtazapine for any indication, including insomnia. This is not a recognized or guideline-supported treatment strategy.

What the Evidence Actually Supports

For Insomnia Treatment Alone

If the primary problem is chronic insomnia (not depression), mirtazapine monotherapy has emerging evidence:

• A 2025 randomized controlled trial in older adults showed mirtazapine 7.5 mg reduced Insomnia Severity Index scores by 6.5 points versus 2.9 for placebo at 28 days 2
• Another 2025 trial found mirtazapine 7.5-15 mg provided clinically relevant improvement at 6 weeks, though benefits diminished at later timepoints 3
• However, major clinical practice guidelines do not recommend mirtazapine for insomnia. The 2017 American Academy of Sleep Medicine guideline specifically recommends against using trazodone (another sedating antidepressant) for insomnia 4, and does not include mirtazapine in their recommendations at all

Guideline-supported options for chronic insomnia include:

• Eszopiclone, zolpidem, zaleplon (for sleep onset)
• Suvorexant (for sleep maintenance)
• Low-dose doxepin 3-6 mg (for sleep maintenance)
• All carry WEAK recommendations per AASM guidelines 4

For Depression with Insomnia

If the patient has major depressive disorder with insomnia as a symptom:

• Vortioxetine is FDA-approved for MDD but has minimal effect on insomnia specifically. The FDA label notes insomnia occurred in only 2.0-5.1% of vortioxetine patients versus 4.0% for placebo 5
• Mirtazapine monotherapy showed benefit for both depression and insomnia in a 2026 open-label study, with 62.4% achieving insomnia remission and 41.3% depression remission at 6 weeks 6
• Switching from vortioxetine to mirtazapine would be more rational than combining them if insomnia is prominent

Common Pitfalls to Avoid

1. Polypharmacy without evidence: Adding medications without clear benefit increases adverse event risk
2. Ignoring cognitive-behavioral therapy for insomnia (CBT-I): This remains first-line treatment but wasn't requested here
3. Using antidepressants off-label for insomnia when FDA-approved options exist: Guidelines favor agents with proven efficacy for insomnia specifically 7, 4
4. Missing serotonin syndrome symptoms: Agitation, confusion, tremor, hyperthermia, hyperreflexia require immediate discontinuation

Practical Recommendation

Choose one agent based on the primary diagnosis:

• If MDD is primary: Continue vortioxetine and add a guideline-supported hypnotic (suvorexant, low-dose doxepin, or a Z-drug) if insomnia persists 4
• If insomnia is primary or equal: Consider switching to mirtazapine monotherapy 7.5-15 mg, which addresses both conditions 2, 3, 6
• Never combine vortioxetine with mirtazapine due to serotonin syndrome risk and lack of supporting evidence 1